Rhythm Pharmaceuticals, Inc. Form 4 Filings

RHYTHM PHARMACEUTICALS, INC. (RYTM) Chief Financial Officer Hunter C. Smith exercised 57,187 employee stock options on August 31, 2026 at an exercise price of $25.79 per share, receiving the same number of common shares. On the same date, he sold 62,774 common shares in multiple transactions at weighted average prices around $104.59, $105.37, and $106.20 per share, with each tranche executed in price ranges disclosed in the footnotes. The option exercised was granted on February 14, 2018 and vesting occurred in sixteen equal quarterly installments; 3,813 option shares remain outstanding, expiring February 13, 2028. All exercises and sales were made pursuant to a Rule 10b5-1 trading plan adopted on May 13, 2026.

RHYTHM PHARMACEUTICALS, INC. (RYTM) reported that Chief Medical Officer Manher Joshi received equity awards. He was granted 50,000 stock options with an exercise price of $115.44 per share, expiring August 16, 2036. These options vest 25% after one year, then 6.25% every three months of continued service.

He also received 25,000 Restricted Stock Units, vesting 25% on September 1 of each of 2027, 2028, 2029, and 2030, becoming fully vested on September 1, 2030, subject to continued service. Following these grants, he holds 50,000 options and 25,000 RSUs directly.

RHYTHM PHARMACEUTICALS, INC. executive Joseph Shulman, Chief Technical Officer, exercised 2,024 stock options at an exercise price of $6.80 per share into common stock on 2026-08-13 and sold 5,079 common shares at $119.75 per share. The options, granted on 2022-02-09 and vesting in 16 installments, now show 5,945 options reported as remaining. These transactions were effected under a Rule 10b5-1 trading plan adopted on 2025-12-15.

RHYTHM PHARMACEUTICALS, INC. executive Alastair Garfield, Chief Scientific Officer, reported selling a total of 7,763 shares of common stock on August 13, 2026 in four open‑market or private transactions. The sales, made under a Rule 10b5-1 trading plan adopted on May 14, 2026, occurred at weighted average prices of $116.1093, $117.0759, $118.2843, and $119.1688 per share, each representing multiple trades within stated price ranges.

Rhythm Pharmaceuticals EVP Jennifer Kayden Lee reported multiple transactions in company equity on August 13, 2026. She exercised stock options covering 56,601 shares of common stock at exercise prices of $24.29 and $6.80 per share, receiving the corresponding common shares. She then sold 75,834 shares of common stock at a price of $117.3818 per share. All exercises and sales were effected pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2026.

Rhythm Pharmaceuticals EVP Yann Mazabraud exercised stock options to acquire 46,625 shares of common stock at an exercise price of $6.80 per share and reported continuing to hold 35,875 stock options after the exercise. On the same date, he sold an aggregate of 57,000 shares of common stock in multiple open-market transactions at weighted-average prices ranging from approximately $111.58 to $117.60 per share. The exercise and sales were effected pursuant to a Rule 10b5-1 trading plan adopted on May 13, 2026, and the options exercised were part of a grant made on February 9, 2022 that vests in substantially equal quarterly installments.

Rhythm Pharmaceuticals Chief Scientific Officer Alastair Garfield reported routine equity compensation activity involving restricted stock units and related tax withholding. On July 1, 2026, he exercised 4,445 restricted stock units, each converting into one share of common stock, increasing his direct common stock holdings to 12,208 shares.

To cover withholding taxes on this vesting, 2,150 common shares were withheld, classified as a tax-withholding disposition rather than an open-market sale. Following these transactions, Garfield also holds 8,888 restricted stock units, which vest in four equal annual installments of 25% each starting from July 1, 2024, contingent on his continued service.

RHYTHM PHARMACEUTICALS director Jean Christophe reported equity awards and an RSU conversion into common stock. He received 2,324 restricted stock units, each representing one share of common stock, which fully vest upon the earlier of June 24, 2027 or the day before the 2027 annual meeting, subject to continued service.

He also received stock options for 3,691 shares of common stock at an exercise price of $107.55 per share, vesting on the same schedule and expiring on June 23, 2036. In addition, 4,712 previously granted restricted stock units were exercised and converted into 4,712 shares of common stock, leaving no remaining units from that grant. Following these transactions, he holds 11,712 shares of common stock directly.

RHYTHM PHARMACEUTICALS director David W. J. McGirr reported equity compensation and an option-related share issuance. On June 24, 2026, he received 2,324 Restricted Stock Units and a stock option for 3,691 shares of common stock with an exercise price of $107.55 per share, both as grants.

On June 23, 2026, he exercised 4,712 Restricted Stock Units, receiving the same number of common shares, increasing his direct common stock holdings to 11,712 shares. The new option and RSU awards generally vest by June 24, 2027 or immediately before the issuer’s 2027 annual stockholder meeting, subject to his continued service.

RHYTHM PHARMACEUTICALS director Lynn A. Tetreault received new equity awards and exercised existing units. On June 24, 2026, she was granted 2,324 restricted stock units and options for 3,691 shares of common stock at an exercise price of $107.55 per share. The options and these RSUs vest in full on the earlier of June 24, 2027 or the day immediately prior to the company’s 2027 annual stockholder meeting, subject to her continued board service.

On June 23, 2026, 4,712 restricted stock units were converted into 4,712 shares of common stock, leaving no remaining units from that grant. Following these transactions, she directly holds 11,712 shares of common stock.

RHYTHM PHARMACEUTICALS director Stuart A. Arbuckle reported equity-based compensation and an option exercise. He received 2,324 restricted stock units (RSUs) and stock options for 3,691 shares of common stock at an exercise price of $107.55 per share, expiring on June 23, 2036. He also exercised 4,712 RSUs into 4,712 shares of common stock, bringing his direct common stock holdings to 11,712 shares. The new RSUs and options generally vest in full by June 24, 2027, subject to continued service.

RHYTHM PHARMACEUTICALS director Jennifer L. Good reported equity awards and an option-related share issuance. On June 24, 2026, she received 2,324 restricted stock units and options for 3,691 shares of common stock at an exercise price of $107.55 per share. The new RSUs and options fully vest on the earlier of June 24, 2027 or the day immediately before the company’s 2027 annual stockholder meeting, subject to her continued service. On June 23, 2026, 4,712 previously granted RSUs were converted into 4,712 shares of common stock, increasing her direct common stock holdings to 11,712 shares.

Rhythm Pharmaceuticals director Lynn A. Tetreault reported an exercise-and-sell transaction in company stock. On June 22, 2026, she exercised stock options to acquire 37,000 shares of common stock at $28.27 per share and sold 37,000 shares in open-market transactions at a weighted average price of $100.3215 per share. The sales were executed under a Rule 10b5-1 instruction adopted on December 15, 2025. Following these transactions, she directly holds 7,000 shares of common stock.

Rhythm Pharmaceuticals Chief Financial Officer Hunter C. Smith exercised stock options for 3,000 shares of Common Stock at an exercise price of $17.87 per share. This moved 3,000 shares from options into directly held stock, with no shares reported sold in this filing.

Following the transaction, Smith directly owns 119,611 shares of Common Stock and 79,000 stock options that remain outstanding and fully vested. The exercised options were already fully vested, indicating this was a routine conversion of derivative awards into common shares rather than an open-market purchase or sale.

Rhythm Pharmaceuticals Corporate Controller & CAO Christopher Paul German reported same-day option exercises and a share sale. He exercised stock options for an aggregate 4,442 shares of Common Stock at exercise prices of $17.97, $49.23, and $56.69 per share.

On May 15, 2026, he then completed an open-market sale of 4,643 Common Stock shares at an average price of $92.21 per share, leaving 0 shares of Common Stock held directly after the transactions. He continues to hold stock options, including 2,325, 2,701, and 3,713 options from grants made in 2023, 2024, and 2025, subject to the vesting schedules described.

Rhythm Pharmaceuticals EVP exercises restricted stock units into shares

Executive Vice President and Head of International Yann Mazabraud exercised restricted stock units that convert into common stock of Rhythm Pharmaceuticals. On April 1, 2026, he converted 10,375 and 2,500 restricted stock units into common shares at an exercise price of $0.00 per share.

Following these derivative exercises, his direct holdings increased to 66,030 shares of common stock. Each restricted stock unit represents a contingent right to receive one share of common stock and vests in four annual installments between April 2024 and April 2028, with no expiration date stated for the units.

RHYTHM PHARMACEUTICALS, INC. director Kimberly J. Popovits received equity-based compensation on April 1, 2026. She was granted 6,808 Restricted Stock Units, each representing a right to receive one share of common stock.

The RSUs vest in three equal installments of 33% on April 1, 2027, April 1, 2028, and April 1, 2029, provided she continues in service. She was also granted 10,257 stock options with an exercise price of $88.12 per share, vesting in three substantially equal annual installments and expiring on March 31, 2036.

Rhythm Pharmaceuticals director Edward T. Mathers reported an internal restructuring of his related holdings. NEA Partners 13, L.P. made a pro rata, no‑consideration distribution of Rhythm common stock to its limited partners, and the Edward Timothy Mathers Revocable Trust received 4,199 shares.

Mathers is trustee of this trust, which now indirectly holds 14,168 shares of Rhythm common stock, while he also directly holds 7,000 shares

Rhythm Pharmaceuticals corporate controller Christopher Paul German reported option exercises and share sales. On March 4, 2026, he exercised stock options for 1,500 shares at an exercise price of $17.97 per share, converting derivative awards into common stock.

That same day, he sold 5,614 shares of common stock in open-market transactions at $89.56 per share, leaving 160 shares of common stock held directly after the sale. A footnote notes that his holdings include 21 shares purchased through the employee stock purchase plan and that the options vest in scheduled installments through March 20, 2027.

Rhythm Pharmaceuticals executive Yann Mazabraud received a grant of 35,000 stock options on March 2, 2026. The options carry an exercise right to buy company stock at a set price and were awarded at no cost. They vest in 16 substantially equal installments, each after three full months of continued service to the company, tying the award to ongoing employment.

Rhythm Pharmaceuticals director Edward T. Mathers reported an other type of insider transaction involving common stock. On March 2, 2026, NEA Partners 13, L.P. made a pro rata, no‑consideration distribution of Rhythm shares to its limited partners, and the Edward Timothy Mathers Revocable Trust received 4,198 shares. Mathers is trustee of this trust, which held 9,969 Rhythm shares indirectly after the transaction, while he also held 7,000 shares directly. He disclaims beneficial ownership of any portion of the trust’s holdings in which he has no pecuniary interest.

Rhythm Pharmaceuticals Corporate Controller and Chief Accounting Officer Christopher Paul German reported routine equity compensation activity. On March 1, 2026, he exercised 1,162 restricted stock units, receiving the same number of common shares at $0.00 per share. Of these, 342 common shares were automatically withheld at $94.94 per share to cover tax obligations, rather than sold on the open market. After these transactions, he directly owned 4,253 shares of common stock. The underlying restricted stock units vest in four equal 25% installments on March 20, 2024, March 20, 2025, March 1, 2026, and March 1, 2027, contingent on continued service.

Rhythm Pharmaceuticals' Chief Financial Officer Hunter C. Smith acquired shares through an option exercise. On March 2, 2026, Smith exercised stock options for 6,099 options, which converted into 6,099 shares of common stock at an exercise price of $6.80 per share.

After these transactions, Smith directly held 91,401 stock options and 116,611 shares of common stock. The filing notes that the options involved in this exercise were fully vested.

Rhythm Pharmaceuticals Chief Financial Officer Hunter C. Smith reported open-market sales of a total of 7,954 shares of common stock on February 17 and 19, 2026, at prices generally around $100 per share.

The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2025. After these sales, Smith directly holds 110,512 shares of Rhythm Pharmaceuticals common stock.

Rhythm Pharmaceuticals EVP Yann Mazabraud reported equity award activity involving restricted stock units and common stock. On February 14, 2026, he exercised or converted 10,000 restricted stock units into 10,000 shares of common stock at a price of $0.00 per share, reflecting the non-cash nature of the award.

After these transactions, he directly held 30,000 restricted stock units and 53,155 shares of common stock. Each restricted stock unit represents a right to receive one share of common stock and vests in four 25% installments on February 14, 2026, February 1, 2027, February 1, 2028, and February 1, 2029.

Shulman Joseph, Chief Technical Officer of Pharmaceuticals, Inc., reported new equity awards. On February 11, 2026, he received 15,000 restricted stock units and stock options for 22,500 shares with a $98.47 exercise price, all held directly.

The restricted stock units vest in four equal 25% installments on February 1 of 2027, 2028, 2029 and 2030 and have no expiration date. The options were granted on February 11, 2026 and vest in 16 substantially equal installments, each after three full months of continued service, until fully exercisable by February 10, 2036.

RYTM Pharmaceuticals’ President and CEO David P. Meeker reported equity awards consisting of restricted stock units and stock options. On February 11, 2026, he received 71,900 restricted stock units, each representing the right to receive one share of common stock. These units vest 25% each on February 1, 2027, 2028, 2029 and 2030.

On the same date, he was also granted 107,850 stock options with an exercise price of $98.47 per share. These options vest in 16 substantially equal quarterly installments, based on completing each three full months of successive service after the grant date. Both awards are held directly.

Mazabraud Yann reported acquisition or exercise transactions in this Form 4 filing.

Pharmaceuticals, Inc. executive Yann Mazabraud, EVP and Head of International, reported receiving a grant of 23,350 restricted stock units on February 11, 2026. This was an award of derivative securities at a reported price of $0 per unit, held as direct ownership.

The restricted stock units give a contingent right to receive one share of common stock for each unit. They vest in four equal installments of 25% of the total grant on March 1, 2027, February 1, 2028, February 1, 2029, and February 1, 2030, and have no expiration date.

Rhythm Pharmaceuticals executive Jennifer Kayden Lee received new equity awards tied to her role as EVP, Head of North America. On February 11, 2026, she was granted 21,650 restricted stock units, each representing one share of common stock, and 32,500 stock options with a $98.47 exercise price.

The restricted stock units vest in four equal 25% installments on February 1, 2027, 2028, 2029, and 2030 and have no expiration date. The stock options expire on February 10, 2036 and vest in 16 substantially equal installments, each after three full months of continued service following the grant date. All awards are held directly.

German Christopher Paul reported acquisition or exercise transactions in a Form 4 filing for RYTM. The filing lists transactions totaling 5,215 shares. Following the reported transactions, holdings were 5,215 shares.

Rhythm Pharmaceuticals’ Chief Scientific Officer Alastair Garfield received new equity awards. On February 11, 2026, he was granted 16,650 restricted stock units, each representing one share of common stock, and 25,000 stock options with an exercise price of $98.47 per share.

The restricted stock units vest in four equal 25% installments on February 1, 2027, 2028, 2029 and 2030. The options expire on February 10, 2036 and vest in 16 substantially equal installments, each after three full months of continued service following the grant date.

Rhythm Pharmaceuticals’ Chief Human Resources Officer Pamela J. Cramer received new equity awards. On February 11, 2026, she was granted 11,650 restricted stock units, each representing one share of common stock. These RSUs vest in four equal 25% installments on February 1 of 2027, 2028, 2029, and 2030.

She was also granted stock options for 17,500 shares of common stock at an exercise price of $98.47 per share. These options vest in 16 substantially equal installments, based on completing each three full months of successive service after the grant date. All awards are held directly.

Rhythm Pharmaceuticals’ Chief Financial Officer Hunter C. Smith reported multiple open-market sales of common stock on February 10–12, 2026. These sales, executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2025, left him holding 118,466 shares directly.

On February 11, 2026, Smith also received equity compensation in the form of 25,000 restricted stock units and stock options for 37,500 shares at an exercise price of $98.47. The RSUs vest in four equal annual installments from February 1, 2027 through February 1, 2030, while the options vest in 16 substantially equal quarterly installments after the grant date.

The Chief Financial Officer of a biopharmaceutical issuer filed a Form 4 showing open-market sales of common stock on February 4–5, 2026. On February 4, the officer sold 1,500 shares at a weighted average price of $104.7434, 1,000 shares at $106.604, and 747 shares at $107.6654. On February 5, the officer sold an additional 3,381 shares at $106.063.

After these transactions, the officer directly beneficially owned 125,537 shares of common stock. The filing notes that the sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2025, and that each reported price is a weighted average for multiple trades within the stated price ranges.

EVP, Head of International Yann Mazabraud reported an equity award transaction involving restricted stock units and common stock of Pharmaceuticals, Inc. (ticker RYTM). On February 1, 2026, 5,500 restricted stock units were converted into 5,500 shares of common stock at $0 per share under transaction code M.

Following this transaction, Mazabraud directly beneficially owned 43,155 shares of common stock and 11,000 restricted stock units. Each restricted stock unit represents the right to receive one share of common stock, vesting in 25% increments on February 16, 2025, and February 1 of 2026, 2027, and 2028.

The Chief Financial Officer, Hunter C. Smith, reported equity compensation activity involving company stock on February 1, 2026. He converted 26,000 shares of common stock from restricted stock units, bringing his directly held common shares to 132,165 after the reported transactions.

To cover withholding taxes upon vesting, 10,750 common shares were withheld at a price of $108.99 per share, rather than being sold in the open market. The underlying restricted stock units convert into one share of common stock each and vest in four equal annual installments, with various grants vesting through February 2029. The restricted stock units have no expiration date.

Pharmaceuticals, Inc. Chief Technical Officer Joseph Shulman reported the vesting of 16,968 shares of common stock on February 1, 2026 from multiple restricted stock unit (RSU) awards. Each RSU converts into one share of common stock.

To satisfy withholding taxes on this vesting, 6,507 shares were withheld at $108.99 per share. After these transactions, Shulman directly beneficially owned 18,970 shares of common stock and continues to hold additional RSUs that vest in stages through 2029.

Rhythm Pharmaceuticals President and CEO David P. Meeker reported the vesting and conversion of restricted stock units into common stock on February 1, 2026. A total of 68,713 restricted stock units were exercised into common shares, and 31,522 shares were withheld at $108.99 per share to satisfy tax obligations. Following these transactions, Meeker directly holds 239,016 shares of common stock and 156,637 restricted stock units.

Pharmaceuticals, Inc.’s EVP and Head of North America, Jennifer Kayden Lee, reported routine equity activity on February 1, 2026. Restricted stock units converted into 22,612 shares of common stock, increasing her directly held stake before tax withholding.

To cover withholding taxes on the vesting, 9,237 common shares were withheld at $108.99 per share, leaving her with 19,233 shares of common stock held directly after the transactions. Several restricted stock unit awards continue to vest annually through dates ranging from February 1, 2027 to February 1, 2029, with remaining balances including 4,512, 11,000, and 27,487 restricted stock units.

Rhythm Pharmaceuticals, Inc. Corporate Controller & CAO Christopher Paul German reported routine equity compensation activity on February 1, 2026. A total of 3,613 shares of common stock were acquired upon the vesting and settlement of restricted stock units at an exercise price of $0.

The company then withheld 1,138 shares at a price of $108.99 to cover tax obligations tied to this vesting. After these transactions, German directly owned 3,433 shares of common stock, including 36 shares previously purchased through the employee stock purchase plan, plus ongoing holdings of restricted stock units that vest in annual 25% installments through 2029.

Pharmaceuticals, Inc.’s Chief Scientific Officer Alastair Garfield reported a routine equity compensation event. On February 1, 2026, 6,663 restricted stock units (RSUs) were converted into 6,663 shares of common stock at an exercise price of $0. Of these, 2,026 shares were withheld at $108.99 per share to cover tax withholding, leaving Garfield with 7,763 shares of common stock directly owned. He also directly holds 19,987 RSUs, which vest in four equal 25% installments on February 1 of 2026, 2027, 2028, and 2029, with no expiration date.

Pharmaceuticals, Inc. Chief Human Resources Officer Pamela J. Cramer reported equity compensation activity on February 1, 2026. She exercised restricted stock units into 13,293 shares of common stock and then had 4,731 shares of common stock withheld at $108.99 per share to cover tax obligations.

Following these transactions, she directly owned 29,376 shares of common stock. Several restricted stock unit awards continue to vest in 25% increments on specified dates from February 2026 through February 2029, each unit representing a right to receive one share of common stock.

Rhythm Pharmaceuticals' Chief Human Resources Officer, Pamela J. Cramer, reported an option exercise and share sale involving the company’s common stock.

On 12/11/2025, she exercised 3,350 stock options at $27.35 per share, acquiring 3,350 shares, and then sold 3,350 common shares at $111 per share under a Rule 10b5-1 trading plan adopted on August 7, 2025. Following these transactions, she directly held 20,814 common shares and 8,375 stock options expiring on 01/31/2033, which were granted on 02/01/2023 and vest in 16 substantially equal installments based on continued service.

Rhythm Pharmaceuticals (RYTM) reported an insider equity transaction by its Chief Human Resources Officer. On 11/20/2025, the officer exercised 3,350 stock options at an exercise price of $27.35 per share and acquired the same number of common shares. On the same date, 3,350 common shares were sold at a price of $105 per share under a pre-arranged Rule 10b5-1 trading plan adopted on August 7, 2025.

After these transactions, the officer beneficially owned 20,814 shares of common stock directly and held 11,725 stock options that remain beneficially owned. The options exercised on November 20, 2025 were part of a grant made on February 1, 2023 that vests in 16 substantially equal quarterly installments, tied to continued service with the company.

Rhythm Pharmaceuticals (RYTM) insider activity: Chief Human Resources Officer Pamela J. Cramer reported option exercises and open‑market sales. On 11/07/2025, she exercised 8,805 options at $19.02 and 10,546 options at $6.80, then sold 19,351 shares at a weighted average price of $98.8231. On 11/10/2025, she exercised 3,515 options at $6.80 and sold 3,515 shares at $100.00.

Following these transactions, directly held common shares were 20,814. The sales were effected under a Rule 10b5‑1 trading plan adopted on August 7, 2025.

Derivative updates: post‑exercise, option holdings were 5,257 at a $19.02 strike (expires 07/25/2031) and 7,035 and 3,520 at a $6.80 strike (expire 02/08/2032). The filing notes one option grant is fully vested and another vests in 16 equal quarterly installments from February 9, 2022.

Rhythm Pharmaceuticals (RYTM) Chief Technical Officer Joseph Shulman filed a Form 4 detailing an option exercise and same‑day sale on 10/30/2025. He exercised 9,748 stock options at $30.66 and then sold 9,748 common shares at a weighted average price of $115.2439.

The sales were executed in multiple trades between $115.00 and $115.73 and were made pursuant to a Rule 10b5‑1 plan adopted on August 8, 2024. Following these transactions, Shulman beneficially owns 8,509 shares directly. The reported stock option was fully vested prior to exercise and shows zero derivative securities remaining after the transaction.

Rhythm Pharmaceuticals (RYTM) reported an insider transaction by Chief Technical Officer Joseph Shulman. On 10/28/2025, he exercised employee stock options for 2,094 shares at an exercise price of $27.35 and 721 shares at $30.66, then sold 2,815 shares of common stock at a weighted average price of $115.0089. The sale was made pursuant to a Rule 10b5‑1 trading plan adopted on August 8, 2024.

Following these transactions, Shulman beneficially owned 8,509 shares directly. The filing notes the sales occurred in multiple trades between $115.00 and $115.08. The option grant dated February 1, 2023 vests in 16 substantially equal quarterly installments, and another option referenced is fully vested. Derivative holdings reported after the transactions include option positions totaling 12,563 and 9,748 underlying shares, respectively.

Rhythm Pharmaceuticals (RYTM) reported insider activity by its Chief Technical Officer. On 10/16/2025, the officer exercised stock options for 2,093 shares at $27.35 and 12,344 shares at $30.66, then sold 2,693 shares at a weighted average $110.9482, 8,332 shares at $112.0554, and 3,412 shares at $112.81. The trades were made under a Rule 10b5-1 plan adopted on August 8, 2024. Following the transactions, the officer reported 8,509 shares beneficially owned directly. Option holdings reported after the exercises were 14,657 (at $27.35) and 10,469 (at $30.66).